Over 3 Million Prescriptions in Five Months Since U.S. Launch
More than 80% of New Users Are First-Time Patients, Driving Market Expansion

The oral version of Wegovy, "Wegovy Pill," surpassed 3 million cumulative prescriptions in the United States just five months after its launch. Since its release, this means it has been prescribed approximately once every five seconds.

WeGoBeFeel. Yonhap News

WeGoBeFeel. Yonhap News

View original image

On June 8, Yonhap News Agency reported that Novo Nordisk disclosed this information at the American Diabetes Association (ADA) meeting held in New Orleans, United States, starting June 5.


Wegovy Pill (semaglutide 25mg) is the tablet version of the obesity treatment Wegovy, and was launched in the U.S. market on January 5 of this year. According to Novo Nordisk, cumulative prescriptions for Wegovy Pill in the U.S. surpassed 1 million on March 23, and as of June 2, it had exceeded 3 million.


Notably, over 80% of new prescriptions were issued to patients with no prior experience taking GLP-1 class treatments. Novo Nordisk stated, “This is not a replacement of existing therapies, but rather an expansion of the market.”


Until now, the GLP-1 class obesity treatment market had been dominated by injectable drugs such as Wegovy and Eli Lilly’s Zepbound. However, the injectable format has posed some inconvenience in administration, and the monthly treatment cost exceeds $1,000, making accessibility a concern.


In contrast, Wegovy Pill is a once-daily oral medication, improving convenience. The price is also set lower than existing GLP-1 injectables, ranging from $149 (about 215,000 won) to $299 (about 432,000 won) per month.


The efficacy is also considered comparable to the injectable form. According to clinical trial (OASIS 4) results released by Novo Nordisk, patients who continuously took Wegovy Pill 25mg experienced an average weight loss of about 17%. The average weight loss rate, analyzed regardless of treatment continuation, was about 14%, showing similar effectiveness to the existing Wegovy injectable (2.4mg).



Novo Nordisk plans to launch Wegovy Pill in other countries within the year, based on the product’s success in the U.S. market.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing